KDR and nonpapillary renal cell carcinoma: The reported overexpression of TP in ccRCC provided the opportunity to evaluate 5-FU prodrugs, such as S-1, in combination with tyrosine kinase inhibitors (TKIs) targeting VEGF/VEGF receptor (VEGFR).